U.S. Airlines Stock News

TransMedics Group (TMDX) is back in focus after reporting second quarter 2026 results that combined higher revenue with lower net income, along with a raised lower end for full year revenue guidance. See our latest analysis for TransMedics Group. The mixed second quarter numbers and higher revenue guidance have arrived after a volatile spell for TransMedics Group, with a 19.74% 30 day share price return and a 29.62% 90 day share price return contrasting with a year to date share price return...

Power Integrations recently reported second-quarter 2026 results showing higher sales of US$118.94 million and net income of US$9.83 million, affirmed its US$0.215 per-share dividend for September 30, 2026, issued third-quarter revenue guidance of US$122 million to US$130 million, and filed a US$123.9 million shelf registration for 2,000,000 common shares tied to an ESOP offering. At the same time, the company announced its PowiGaN GaN technology is now rated up to 2,200 V, extending its...

Willdan Group, Inc. reported past second-quarter 2026 results showing sales of US$231.03 million and net income of US$24.35 million, with both basic and diluted earnings per share from continuing operations higher than a year earlier. Alongside these stronger results, Willdan set 2026 net revenue targets of US$415 million to US$430 million, highlighting management’s confidence backed by new contract wins and recent acquisition integration. With Willdan’s updated 2026 net revenue targets now...

Xencor, Inc. reported past second-quarter 2026 results showing a reduced net loss of US$21.73 million, or US$0.29 per share, while its net loss for the first half of 2026 widened to US$150.65 million, or US$1.99 per share. This contrast between an improving quarterly loss and a much larger year-to-date loss highlights the company’s uneven cost profile and execution so far in 2026. We’ll now examine how the narrower quarterly loss but much larger year-to-date loss could influence Xencor’s...

Insider sale and new leases put Brixmor in focus A recent insider sale has put Brixmor Property Group (BRX) on investors’ radar again. Director Michael B. Berman sold 9,000 shares on August 12, while the company highlighted record new leasing commitments. See our latest analysis for Brixmor Property Group. At around US$29.98, Brixmor Property Group’s 1 month share price return is down 7.95%, even though its year to date share price return is up 15.49% and the 5 year total shareholder return...

With global bond yields high and borrowing costs less forgiving, capital is flowing toward companies that can raise productivity rather than just cut expenses. Transformative AI healthcare stocks sit right in that sweet spot. They use data and algorithms to help doctors work faster and more accurately, which can appeal when every dollar needs to work harder. This article highlights three AI healthcare stocks from our screener to watch closely. The three stocks below are just a sample from...

Xenon Pharmaceuticals (NasdaqGM:XENE) is back in focus after reporting a second quarter net loss of US$110.74 million and preparing to present at Stifel’s 2026 Biotech Summer Summit on August 10 in Newport. See our latest analysis for Xenon Pharmaceuticals. Despite the wider loss, Xenon Pharmaceuticals shares have cooled in the last month with a 1-month share price return of down 8.66% and a 7-day move of down 1.59%. However, the 90-day share price return of 16.09% and 1-year total...

Babcock & Wilcox Enterprises (BW) is back in focus after agreeing with Siemens Energy to start work on 20 steam turbine generator sets for data center projects, alongside higher financial guidance and a sizeable project pipeline. See our latest analysis for Babcock & Wilcox Enterprises. Those Siemens Energy turbines and the stronger guidance seem to be feeding into the price action. Babcock & Wilcox Enterprises now trades at US$10.29, with a 1 day share price return of 10.05% and a year to...

Kimco Realty (KIM) drew fresh attention after raising its full year 2026 net income guidance and lifting its quarterly dividend by 12%. These updates highlighted management’s current outlook and cash returns to shareholders. See our latest analysis for Kimco Realty. At a share price of $24.41, Kimco Realty has combined a 21.68% year to date share price return with a 20.49% total shareholder return over the past year. This points to momentum that has remained broadly supportive through recent...

In the first quarter ended June 30, 2026, Quantum Corporation reported revenue of US$80.8 million, up from US$64.29 million a year earlier, alongside a net loss of US$155.29 million and a basic loss per share from continuing operations of US$7.06. Despite the wider loss, Quantum issued fiscal second-quarter 2027 revenue guidance of about US$82.0 million and pointed to a record backlog, a cleaner balance sheet, and easing supply constraints that analysts say are reshaping expectations for...

Innoviva, Inc. has reported past second-quarter 2026 results showing revenue of US$119.59 million, up from US$100.28 million a year earlier, but shifting from a net income of US$63.69 million to a net loss of US$83.42 million, while also completing a share repurchase of 3,055,966 shares for US$66.40 million under its existing program. Despite the quarterly loss, Innoviva’s six-month figures to June 30, 2026 show revenue rising to US$217.59 million and net income increasing to US$103.18...

In August 2026, Cohen & Steers, Inc. launched the Cohen & Steers Real Assets Active ETF (CSRA) on NYSE Arca, offering actively managed, diversified exposure across listed real estate, infrastructure, natural resources and commodities. This launch consolidates several real-asset exposures into a single ETF, potentially simplifying portfolio construction for investors already using Cohen & Steers’ broader active ETF lineup. We’ll now examine how the CSRA real assets launch could influence...

In August 2026, Warrior Met Coal, Inc. reported that second-quarter revenue rose to US$509.69 million and net income to US$87.43 million, with basic earnings per share from continuing operations increasing to US$1.65 compared with US$0.11 a year earlier. The company also grew production volumes, returned to profitability for the first half of the year, and raised its full‑year coal sales guidance after stronger‑than‑expected customer adoption of Blue Creek volumes. Now, we’ll examine how...

In early August 2026, Otter Tail Corporation reported second-quarter results showing revenue of US$334.38 million but a net loss of US$7.61 million, cut its 2026 diluted earnings per share guidance to a range of US$3.84 to US$4.24, and declared a quarterly dividend of US$0.5775 per share payable in September. The combination of a quarterly loss tied to settlement-related expenses, a lower full-year earnings outlook, and an ongoing cash dividend highlights the tension between Otter Tail’s...

Flotek Industries, Inc. recently reported past second-quarter 2026 results showing higher revenue and net income year over year, raised its 2026 total revenue guidance to US$340 million–US$350 million, and secured a 10-year Puerto Rico power project agreement expected to create about US$400 million in revenue backlog. Together, the upgraded outlook and long-term Puerto Rico contract highlight a shift toward more recurring, infrastructure-linked revenues that could reshape how investors...

Arlo Technologies (ARLO) recently reported second quarter 2026 results, highlighting record subscriptions and services revenue, steady earnings per share, and a higher full year outlook for both revenue and diluted EPS. See our latest analysis for Arlo Technologies. At a share price of $14.33, Arlo Technologies has seen a 10.66% 90 day share price return and a 7.66% 30 day share price return, while its 5 year total shareholder return of 150.09% contrasts with a 12.99% decline over the past...

BioMarin Pharmaceutical Inc. recently reported second-quarter 2026 results showing revenue of US$989.71 million and lower net income of US$44.76 million, raised its full‑year 2026 revenue guidance to US$3.88 billion–US$3.93 billion, filed a US$719.24 million ESOP‑related shelf registration, and previously presented its outlook at investor conferences. The combination of higher revenue but weaker profitability, alongside management’s expectation that fourth‑quarter sales will contribute well...

Damora Therapeutics (DMRA) has started the global Phase 1/1b CLARITY-101 trial of DMR-001, an investigational antibody that targets mutant calreticulin in essential thrombocythemia and myelofibrosis, representing a rare targeted approach in these blood disorders. See our latest analysis for Damora Therapeutics. At a recent share price of US$31.04, Damora Therapeutics has seen strong momentum, with a 90 day share price return of 24.66% and a very large 1 year total shareholder return that...

Sticky price pressures on essentials, hotter New York inflation and shaky consumer confidence are putting household budgets under real strain, which can reshuffle where every dollar goes. That tension creates both risk and potential openings for investors watching value focused retailers. This article walks through three U.S. discount and value stocks that screens suggest are positively exposed to the latest inflation and employment data, and explains what that could mean for your...

Suburban Propane Partners, L.P. reported past third‑quarter 2026 results with revenue of US$261.38 million and a net loss of US$17.53 million, while nine‑month revenue reached US$1.18 billion with net income of US$165.8 million. An interesting contrast is that the partnership recorded a wider quarterly loss even as nine‑month earnings per unit from continuing operations increased versus the prior year. We’ll now explore how the wider quarterly loss alongside stronger nine‑month earnings...

Inflation above 3%, expensive fuel and a war-driven energy shock are squeezing household budgets and reshaping which U.S. stocks carry the most risk and potential resilience. Energy producers and infrastructure players sit right in the crosshairs of these forces. This article explains how that backdrop relates to three U.S. energy stocks exposed to the news and why their stories may be relevant for your portfolio decisions today. The stocks highlighted below are just a sample. The full screen...

Annexon (ANNX) is back in focus after a busy August, with a key update to its Phase 3 ARCHER II trial for vonaprument, fresh Guillain-Barré data, Q2 earnings, and a boardroom change drawing investor attention. See our latest analysis for Annexon. Over the past year Annexon has shifted from a relatively muted share price pattern to strong momentum, with a 12.79% year to date share price return and a very large 1 year total shareholder return of 116.80%, even though the 5 year total shareholder...

Adeia Inc. recently reported its second-quarter 2026 results, with sales of US$96.12 million and net income of US$17.37 million, declared a US$0.05 per-share dividend, reiterated full-year 2026 revenue guidance of US$395.00–US$435.00 million and net income of US$57.20–US$80.40 million, and confirmed progress on its multi-year share repurchase program. The combination of higher year-on-year sales and net income, continued dividend payments, and ongoing buybacks highlights Adeia’s focus on...

Lindblad Expeditions Holdings recently reported second-quarter 2026 results, with sales rising to US$199.25 million and quarterly net loss shrinking to US$1.41 million, alongside first-half 2026 net income of US$5.09 million. The company also issued full-year 2026 tour revenue guidance of US$830 million to US$860 million, giving investors a clearer view of expected business activity. We’ll now examine how the new full-year revenue guidance and improving first-half profitability could reshape...